Skip to main content
. 2014 Nov;51(5):615–625. doi: 10.1165/rcmb.2014-0049OC

Figure 4.

Figure 4.

High-dose Gas6 suppresses inflammatory response and subsequent AHR and induces severe mucus production in airway. (A) AHR to a methacholine challenge was determined in A. fumigatus–sensitized mice with PBS (-) as a control or with (+Gas6) intranasal challenges with recombinant Gas6 (1 μg/dose × 7 doses = 7.0 μg total) at Day 28 after conidia challenge. (B) Representative hematoxylin and eosin–stained lung tissue sections from control and Gas6-treated groups at Day 28 after conidia challenge. Original magnification: ×100 (upper) and ×400 (lower). (C) BAL cell counts from both groups of mice. (D and E) Whole lung transcript (D) and protein (E) levels of IL-1β, IL-6, IL-12p40, and TNF-α in control and Gas6-treated groups at Day 28 after conidia challenge. (F and G) Whole lung transcript (F) and protein (G) levels of IL-4, IL-5, IL-10, and IL-13 in control and Gas6-treated groups at Day 28 after conidia challenge. (I) Representative PAS-stained lung tissue sections from control and Gas6-treated groups at Day 28 after conidia challenge. Original magnification: ×400. (J) Quantitative pathological analysis of mucus area in I. Results are expressed as the mean ± SEM for n = 5 per group. *P < 0.05, **P < 0.01, and ***P < 0.001 versus control (indicated as -).